Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis? @Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats) Something to consider in these difficult-to-treat pts? @LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU